Q2 FY27 revenue rises 25%; management targets 38-40% EBITDA margin

Management guided margin improvementManagement guided margin pressureInvestor Communications View source PDF Explain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-46.9%Reaction day

₹1231.60

prior close

₹608.00

announcement price

After-mkt

timing

Nifty Smallcap 250market+2.0%-48.9% vs market

Pharmaceuticals peers, median of 173sector+0.8%-47.7% vs sector

On the reaction day the stock moved 48.9 pts less than Nifty Smallcap 250 and 47.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.6

10m

+0.2

15m

-0.7

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-46.9+2.0-48.9+0.8-47.7

Next day

-45.4+2.8-48.2+1.6-47.0

-49.0pendingpending+1.5-50.5

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue rose 25% to Rs 309.1 crore and H1 revenue rose 26% to Rs 566.6 crore. Q2 EBITDA was Rs 104.4 crore and profit after tax was Rs 69.6 crore. Gross margin fell about 400 basis points to 76.2% on higher raw material and power costs. Management expects the full-year impact to ease and targets 38-40% EBITDA over the next few years.

Likely market impact

Strong growth and a zero-debt balance sheet support the stock, while input costs and new-plant ramp-up create near-term risks.